Cargando…
Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis
Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology, characterized by the presence of inflammatory synovitis accompanied by destruction of joint cartilage and bone. Treatment with vasoactive intestinal peptide (VIP) prevents experimental arthritis in animal models by downregulatio...
Autores principales: | Juarranz, Yasmina, Abad, Catalina, Martinez, Carmen, Arranz, Alicia, Gutierrez-Cañas, Irene, Rosignoli, Florencia, Gomariz, Rosa P, Leceta, Javier |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1257432/ https://www.ncbi.nlm.nih.gov/pubmed/16207319 http://dx.doi.org/10.1186/ar1779 |
Ejemplares similares
-
The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis
por: Villanueva-Romero, Raúl, et al.
Publicado: (2018) -
Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis
por: Martínez, Carmen, et al.
Publicado: (2014) -
The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP
por: Jimeno, Rebeca, et al.
Publicado: (2014) -
Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis
por: Seoane, Iria V., et al.
Publicado: (2018) -
An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance
por: Gomariz, Rosa P., et al.
Publicado: (2019)